Oluyemi Okupe Sells 11,581 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the transaction, the chief financial officer now owns 118,077 shares of the company’s stock, valued at $2,885,801.88. This trade represents a 8.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.77, for a total transaction of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98.

Hims & Hers Health Stock Up 0.2 %

Shares of Hims & Hers Health stock opened at $27.91 on Friday. Hims & Hers Health, Inc. has a 52 week low of $8.14 and a 52 week high of $35.02. The business has a 50 day moving average price of $27.51 and a 200-day moving average price of $21.76. The company has a market cap of $6.10 billion, a PE ratio of 63.44 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period last year, the business earned ($0.04) EPS. The business’s revenue was up 77.1% on a year-over-year basis. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on HIMS. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, January 6th. Piper Sandler boosted their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Finally, Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $25.13.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in the company. Main Management ETF Advisors LLC bought a new position in shares of Hims & Hers Health during the 3rd quarter worth approximately $672,000. Robeco Institutional Asset Management B.V. bought a new stake in Hims & Hers Health during the third quarter worth $604,000. Carnegie Investment Counsel purchased a new position in Hims & Hers Health in the third quarter worth $5,531,000. Royce & Associates LP increased its position in shares of Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after purchasing an additional 49,500 shares during the last quarter. Finally, Versor Investments LP purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $634,000. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.